### Contents

<table>
<thead>
<tr>
<th>Contributors</th>
<th>page xv</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preface</td>
<td>xix</td>
</tr>
</tbody>
</table>

### SECTION I: TRANSLATIONAL MEDICINE: HISTORY, PRINCIPLES, AND APPLICATION IN DRUG DEVELOPMENT

1. TRANSLATIONAL MEDICINE: DEFINITION, HISTORY, AND STRATEGIES  
   Bruce H. Littman  
   3

1.1. Biomarkers in Drug Development: A Common Understanding  
   5

1.2. Pharmacology: Testing the Target (POM)  
   7

1.3. Study Design Considerations for POM  
   13
   1.3.1. Population  
   13
   1.3.2. Risk  
   14
   1.3.3. Feasibility  
   14
   1.3.4. Endpoints  
   15
   1.3.5. PK–PD and PD–PD Models  
   16

1.4. Confirming the Hypothesis That a Drug Target (Mechanism of Action) Will Be Efficacious (POC)  
   17

1.5. Study Design Considerations for POC  
   17
   1.5.1. Population  
   17
   1.5.2. Efficacy Endpoints  
   19
   1.5.3. Dose Selection  
   20
   1.5.4. Cost, Speed, and Risk  
   20
   1.5.5. Multiple Indications (Serial or Parallel)  
   21
1.6. Human Indications Screening 23
   1.6.1. Expl-IND Application 24
   1.6.2. Low Cost Attrition and Portfolio Economics 26

1.7. Commercial Profile and Translational Medicine 27
   1.7.1. Impact on Survival 27
   1.7.2. Impact on Decision Making 29
   1.7.3. Translational Medicine and the Personalized Medicine Option 31

1.8. Conclusion 32

1.9. References 32

2. TRANSLATIONAL MEDICINE AND ITS IMPACT ON DIABETES
   DRUG DEVELOPMENT Roberto A. Calle and Ann E. Taylor 35
   2.1. Introduction 35
   2.2. Primary Challenges 37
      2.2.1. Efficacy 37
      2.2.2. Safety 46
   2.3. Case Studies 49
      2.3.1. Case Study #1: Development of DPP-4i 49
      2.3.2. Case Study #2: Development of 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors 50
      2.3.3. Case Study #3: Effect of Weight Loss on HbA1c 54
   2.4. Conclusions 56
   2.5. Acknowledgments 56
   2.6. References 56

3. CHALLENGES IN Atherosclerosis John S. Millar 62
   3.1. Introduction 62
   3.2. Prevailing Hypotheses of Atherosclerosis Development 62
      3.2.1. The Lipid Hypothesis 62
      3.2.2. The Response-to-Injury Hypothesis 63
      3.2.3. The Response-to-Inflammation Hypothesis 64
      3.2.4. The Response-to-Retention Hypothesis 64
   3.3. Clinical Trials Supporting the Lipid Hypothesis 65
   3.4. Where We Stand Today 65
3.5. Atherosclerosis and Drug Discovery and Development  67
  3.5.1. Lipoprotein Metabolism  67
  3.5.2. Antidyslipidemics  69
3.6. The Future Generation of LDL-Lowering Drugs  73
  3.6.1. Thyroid Receptor-β Agonism  73
  3.6.2. Lipoprotein-Associated-Phospholipase A2 Inhibitors  73
  3.6.3. Secretory Phospholipase A2 Inhibitors  74
  3.6.4. Microsomal Triglyceride Transfer Protein Inhibitors  74
  3.6.5. Antisense/RNA Interference of apoB mRNA  75
3.7. Therapies to Increase HDL Cholesterol Levels and Improve HDL Function  75
  3.7.1. CETP Inhibitors  76
  3.7.2. PPAR-α Agonists  76
  3.7.3. Reconstituted and Recombinant HDL/apoA-I Mimetic Peptides  77
3.8. Biomarkers Linked to Clinical Outcomes  77
  3.8.1. Biomarkers  78
  3.8.2. Measures of Vascular Function and Atherosclerosis  78
3.9. Case Study: CETP Inhibition with Torcetrapib – Mechanism versus Molecule  80
3.10. Conclusion  82
3.11. References  82

4. OBESITY: NEW MECHANISMS AND TRANSLATIONAL PARADIGMS  Gregory Gaich and David E. Moller 89
4.1. Introduction  89
  4.1.1. Medical Need and History of Failure  89
  4.1.2. Pathophysiology and Principles of Energy Balance  90
4.2. Molecular Pathways and Associated Drug Targets  90
  4.2.1. Central Regulation of Satiety–Thermogenesis  92
  4.2.2. Modulating the Actions of Gut-Derived Peptide Hormones  96
  4.2.3. Targeting Other Peripheral Pathways  98
4.3. Clinical Paradigm and Recent Clinical Experience  100
4.4. Translational Approaches  102
  4.4.1. Target Engagement  103
  4.4.2. Drug Pharmacology or Mechanism Biomarkers  104
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4.3. Disease Process or Outcome Biomarkers and Mechanism Biomarkers.Linked to Efficacy Outcomes</td>
<td>105</td>
</tr>
<tr>
<td>4.4.4. Subject Selection</td>
<td>106</td>
</tr>
<tr>
<td>4.4.5. Combination Therapy</td>
<td>107</td>
</tr>
<tr>
<td>4.5. Concluding Comments</td>
<td>107</td>
</tr>
<tr>
<td>4.6. References</td>
<td>108</td>
</tr>
<tr>
<td>5. BONE DISORDERS: TRANSLATIONAL MEDICINE CASE STUDIES S. Aubrey Stoch</td>
<td>115</td>
</tr>
<tr>
<td>5.1. Introduction</td>
<td>115</td>
</tr>
<tr>
<td>5.2. Challenges in Translational Research</td>
<td>116</td>
</tr>
<tr>
<td>5.3. Osteoporosis: Biomarker Considerations</td>
<td>116</td>
</tr>
<tr>
<td>5.3.1. Biochemical Biomarkers of Bone Turnover</td>
<td>116</td>
</tr>
<tr>
<td>5.3.2. Imaging Biomarkers (BMD)</td>
<td>118</td>
</tr>
<tr>
<td>5.3.3. Preclinical Models</td>
<td>119</td>
</tr>
<tr>
<td>5.4. Antiresorptives</td>
<td>121</td>
</tr>
<tr>
<td>5.4.1. Cat K Inhibitors</td>
<td>122</td>
</tr>
<tr>
<td>5.4.2. $\alpha_v\beta_3$ Integrin Antagonists</td>
<td>127</td>
</tr>
<tr>
<td>5.5. Osteoanabolics</td>
<td>130</td>
</tr>
<tr>
<td>5.5.1. Selective Androgen Receptor Modulators</td>
<td>131</td>
</tr>
<tr>
<td>5.5.2. Calcium Receptor Antagonants (Calcilytics)</td>
<td>136</td>
</tr>
<tr>
<td>5.5.3. Dickkopf-1 (DKK-1) Inhibitors</td>
<td>144</td>
</tr>
<tr>
<td>5.5.4. Sclerostin Inhibitors</td>
<td>149</td>
</tr>
<tr>
<td>5.6. Conclusions</td>
<td>155</td>
</tr>
<tr>
<td>5.7. References</td>
<td>158</td>
</tr>
<tr>
<td>6. CASE STUDIES IN NEUROSCIENCE: UNIQUE CHALLENGES AND EXAMPLES Gerard J. Marek</td>
<td>168</td>
</tr>
<tr>
<td>6.2. Why Have New Mechanisms Failed?</td>
<td>169</td>
</tr>
<tr>
<td>6.3. Can We Predict Efficacy in Short-Term Studies?</td>
<td>173</td>
</tr>
<tr>
<td>6.4. What Is the Role for Cognitive Biomarkers?</td>
<td>174</td>
</tr>
<tr>
<td>6.5. What Translational Medicine Approaches Will Drive Innovation in Neuroscience Drug Development?</td>
<td>175</td>
</tr>
<tr>
<td>6.6. References</td>
<td>177</td>
</tr>
</tbody>
</table>
7. TRANSLATIONAL MEDICINE IN ONCOLOGY  Dominic G. Spinella  180

7.1. Pharmacodynamic Biomarkers  180
  7.1.1. Traditional Phase 1 Dose Selection versus the Paradigm for Targeted Agents  181

7.2. Outcome Biomarkers  183

7.3. Patient Selection Biomarkers  185

7.4. Putting It All Together: The Translational Approach  188
  7.4.1. Preclinical Work  188
  7.4.2. The Phase 1 Study  189
  7.4.3. The Phase 2 Study  190

7.5. Conclusions  190

7.6. References  191

SECTION II: BIOMARKERS AND PUBLIC–PRIVATE PARTNERSHIPS  193

8. BIOMARKER VALIDATION AND APPLICATION IN EARLY DRUG DEVELOPMENT: IDEA TO PROOF OF CONCEPT  Pfizer Global Research and Development 2004  195

8.1. Definitions and Summary of Overarching Principles  195

8.2. Biomarker Validation Terminology  197

8.3. Stages of Biomarker Lifecycle  198

8.4. Why Biomarkers?  200

8.5. Biomarker Validation  202
  8.5.1. Define the Specific Purpose(s) of the Biomarker  202
  8.5.2. Examine the Business Impact of Making a Wrong Decision  203
  8.5.3. Select Appropriate Technical Validation Attributes  205
  8.5.4. Create the Biomarker MAC and Appropriate Decision Criteria  209
  8.5.5. Summary  214

8.6. When and How to Apply Biomarkers in Drug Development: Biomarker Development Is Described for Each Stage of Drug Development  215
  8.6.1. Biomarker Development Must Occur So That Biomarkers Are Validated for Their Purpose Prior to Application for Drug Development Decisions  215
8.6.2. Biomarker Selection and Development between “Target Idea” and Decision on Drug Candidate Selection
8.6.3. Biomarker Best Practice between Drug Candidate Selection and First In-Human (FIH) Study
8.6.4. Biomarker Best Practice between FIH and Phase 2 Start

9. IMAGING BIOMARKERS IN DRUG DEVELOPMENT:
CASE STUDIES Johannes T. Tauscher and Adam J. Schwarz

9.1. Introduction
9.2. Molecular Imaging: PET “Receptor Occupancy” as a Marker for Target Engagement
  9.2.1. A Brief History of Dopamine Receptor Occupancy with Antipsychotics
  9.2.2. Serotonin Transporter Occupancy with Antidepressants
  9.2.3. Case Study of a Translational PET Imaging Biomarker Strategy
9.3. Functional Imaging: fMRI as a Probe of Drug Effects in the CNS
  9.3.1. fMRI Biomarkers and Mechanistic Models in Early Drug Development
  9.3.2. Normalization of Brain Function: fMRI Studies in Patient Populations
  9.3.3. Validation and Standardization of fMRI for Drug Development Applications
9.4. Imaging as a Biomarker to Enrich Study Populations
9.5. Oncology
  9.5.1. Anatomical Imaging in Cancer Drug Development
  9.5.2. Functional Imaging in Cancer Drug Development
  9.5.3. Imaging the Tumor Vasculature
  9.5.4. Imaging of Cellular Proliferation
  9.5.5. Tumor Receptor Imaging
  9.5.6. Imaging Apoptosis
9.6. Imaging Cardiovascular Disease
  9.6.1. Clinical Trials in Atherosclerosis Using Imaging Endpoints
  9.6.2. Practicality of Cardiovascular Imaging Trials and Application to Drug Development
10. EUROPEAN NEW SAFE AND INNOVATIVE MEDICINES INITIATIVES: HISTORY AND PROGRESS (THROUGH DECEMBER 2009) Ole J. Bjerrum and Hans H. Linden 265

10.1. Introduction 265
   10.1.1. The EU Research Funding System 265
   10.1.2. Stakeholders 266

10.2. Toward the IMI 267
   10.2.1. First Round: Establishment of the NSMF Project 267
   10.2.2. Second Round: Incorporation of NSMF in FP 6 269
   10.2.3. Third Round: The Rise of the IMI 271

10.3. Organizational Structure of the IMI 272

10.4. How Does the SRA of the IMI Address Predictive Markers of Efficacy and Safety? 274
   10.4.1. Predictive Markers of Efficacy 274
   10.4.2. Predictive Markers of Safety 276

10.5. How Is Off-Target Toxicity Addressed in the SRA? 277


10.7. The Topic Proposals in the First Call of the IMI 280
   10.7.1. Predictive Safety 281
   10.7.2. Predictive Efficacy 282
   10.7.3. Knowledge Management 283
   10.7.4. Education and Training 283

10.8. The Call Procedures 285

10.9. Future Perspectives 285

10.10. Acknowledgments 287

10.11. References 287

11. CRITICAL PATH INSTITUTE AND THE PREDICTIVE SAFETY TESTING CONSORTIUM Elizabeth Gribble Walker 289

11.1. Introduction to the Critical Path in Medical Product Development 289
11.2. The Predictive Safety Testing Consortium 290
11.3. Regulatory and Public Health Impact of the PSTC 292
11.4. References 293

12. THE BIOMARKERS CONSORTIUM: FACILITATING THE
DEVELOPMENT AND QUALIFICATION OF NOVEL BIOMARKERS
THROUGH A PRECOMPETITIVE PUBLIC–PRIVATE PARTNERSHIP 295
David Wholley and David B. Lee

12.1. References 300

SECTION III: FUTURE DIRECTIONS 301

13. IMPROVING THE QUALITY AND PRODUCTIVITY OF
PHARMACOMETRIC MODELING AND SIMULATION ACTIVITIES:
THE FOUNDATION FOR MODEL-BASED DRUG DEVELOPMENT 303
Thaddeus H. Grasela, Jill Fiedler-Kelly, and Robert Slusser

13.1. Introduction 303
13.1.1. Chapter Overview 304

13.2. The Pharmacometric Analysis Process 304
13.2.1. The M&S Process in Pharmacometrics – Current
Practice 305
13.2.2. The M&S Process in Pharmacometrics – Future
Practice 306
13.2.3. The Central Role of the Franchise Disease–Drug
Model 307
13.2.4. Implications of the Future Scenario 310

13.3. Challenges in the Delivery of M&S Results 311
13.3.1. Systematic Needs 311
13.3.2. Informatics Needs 312
13.3.3. Process Needs 313

13.4. Next Steps 314
13.4.1. Strategies for Improving the Quality and
Productivity of the Pharmacometrics Process 315
13.4.2. Strategies for Improving the Quality and
Robustness of the Informatics Infrastructure for
Pharmacometrics 318
13.4.3. A Systematic Process for Assessing Franchise
Disease–Drug Model Feasibility 319
13.4.4. Systematizing the Requirements Definition
Management Process 322
## Contents

13.5. Summary 324  
13.6. References 325

### 14. EMBRACING CHANGE: A PHARMACEUTICAL INDUSTRY GUIDE TO THE 21ST CENTURY

**Mervyn Turner** 328

14.1. Introduction 328  
14.1.1. Toward a New Paradigm of Drug Development 330  
14.1.2. Embracing Democratization: Partner or Perish 331

14.2. Toward a New Paradigm of Drug Development: It’s a State of Mind 331

14.3. Fail Fast, Fail Cheap 332

14.4. Philosophy in Action: Merck’s Clinical Pharmacology and Experimental Medicine Strategies 334  
14.4.1. Embrace Democratization – Partner or Perish 336  
14.4.2. Adapt Culture to Recognize the Benefits and Necessities of Diversifying Pathways to Knowledge 337  
14.4.3. Advance Experimental Medicine through Acquisition and Partnering 339

14.5. A Blueprint for Change 341

14.6. References 343

*Index* 345